

Update SAC Trial April 2022

Collaborate with



Objective

Evaluation and Comparison of Multiple Myeloma progression by inducing 5TGM1 with Luc cells in NSG mice by the treatment of intraperitoneal injections of SAC

Part 1

TAT/PBS Group IVIS

- ❑ Group-I #125 and #129 (TBT)
- ❑ Group-II #127 and 131 (TAT)
- ❑ Group-III #128 and 130 (PBS)

- ❖ 5TGM1 with Luc inj on 1/14/22 for Groups II and III
- ❖ 5TGM1 with Luc inj on 1/28/22 for Group I
- ❖ IP injection given to all groups daily(M-F)
 - ❖ TBT treatment on 1/17/22
 - ❖ TAT treatment on 1/31/22
 - ❖ PBS (control) begins with TAT
- ❖ IP injection: Sac Formulation (480µg/300µl) was diluted 1:1 with PBS
 - ❖ 600µl injection → adjusting to 300µl injection 2x daily

New Grouping

❑ New Grouping is as follows: (Randomized the PBS and TAT groups)

❖ High Group I (M) • 831, 833, and 842 PBS

• 821 and 844 TAT

❖ High Group II (F) • 822 and 824 PB

• 836 and 837 TAT

❖ Low Group I (M) • 832 and 834 PBS

• 818, 819, and 820 TAT

❖ Low Group II (F) • 823 and 825 PBS

• 838, 839, and 840 TAT


❑ TBT Groups – Remain the same

TAT/PBS Group IVIS


At week 3

The mice we separated based on level of progression.








The cages became High Group I, High Group II, Low Group I, & Low Group II. Abbreviated HGI, HGII, etc





TAT/PBS Group IVIS(cont.)



TAT/PBS Group IVIS(cont.)

	HGI	LGI	LGII
Week 7			
Week 8			
Week 9			

PBS VS. TAT



Log-rank (Mantel-Cox) test
Chi square 4.65
df 1
P value 0.0310
P value summary *
Are the survival curves sig different? Yes

	Control	TaT
Median survival	50.5	62